I have a PhD from the University of Nottingham in designing polymeric nanop文章s for tumour targeting, with my first degree in Pharmacy from India. I joined AstraZeneca in 2008, working on the formulation of clinical 产品介绍s for inhalation.

In 2010, I moved into the Pharmaceutical Development 团队 and worked extensively in the field of advanced nanomedicines and new modalities for oncology therapeutics.

I progressed to the role of Associate Principal Scientist in 2013 and became involved in driving innovative science and implementing clinical development strategies applied to nanomedicines and nucleic acid-based therapeutics.

I moved to Cambridge in 2017 as a team leader of the Advanced Drug Delivery team and established a team of multidisciplinary scientists from leading drug delivery groups with expertise in drug delivery sciences and cell biology.
 

My passion lies in internal and external collaboration, to help identify and implement novel 产品介绍 opportunities that strengthen our pipeline, achieve scientific leadership and ultimately make a meaningful difference to patient health.

Sanya Puri Associate Director, Advanced Drug Delivery, Pharmaceutical Sciences, R&D

皇冠官网地址

CURRENT ROLE

永利皇冠

2018

永利皇冠

2013

永利皇冠

2008

永利皇冠

永利皇冠

Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines.永利皇冠app

Linnane E, Davey P, Zhang P, Puri S,  Edbrooke M, Chiarparin E, Revenko AS, Macleod AR, Norman JC, Ross SJ. Nucleic Acids Research (2019). 9: 4375-4392. Publication link.

CD44 targeted delivery of siRNA by using HA-decorated nanotechnologies for KRAS silencing in cancer treatment.永利皇冠app

Tirella A, Kloc-Muniak K, Good L, Ridden J, Ashford M, Purie S, Tirelli N. International Journal of Pharmaceutics (2019), 561: 114-123. Publication link.

Serum Nuclease susceptibility of mRNA cargo in condensed Polyplexes.永利皇冠app

Yen A, Cheng Y, Sylvestre M, Gustafson HH, Ouri S, Pun SH., Mol. Pharmaceutics (2018), 15:(6), 2268–2276 Publication link.

Evaluation of dynamic contrast-enhanced MRI biomarkers for stratified cancer medicine: How do permeability and perfusion vary between human tumours? 永利皇冠app

Little RA, Barjat H, Hare JI, Jenner M, Watson Y, Cheung S, Holliday K, Zhang W, O’Connor JBP, Barry ST, Puri S, Parker GJM, Waterton JC. Magn Reson Imaging (2018), 46:98-105. Publication link.

Chitosan/Hyaluronic Acid Nanoparticles: Rational Design Revisited for RNA Delivery永利皇冠app

Lallana E, Tirella A, Puri S, Ashford A, Tirelli N, Mol Pharm. (2017), 14(7):2422-2436. Publication link.

Challenges and strategies in anti-cancer nanomedicine development: an industry perspective.永利皇冠app

Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Adv. Drug Deliv Rev (2016) 108, 25-38. Publication link.